Wantstats
Company ProfilePremium

HUTCHMED (China) Limited

Company Profile Analysis

Ticker: 0013.HK和黃醫藥

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
HUTCHMED (China) Limited - Company showcase

Year Founded & Workforce

2000

1,800 Employees

HUTCHMED (China) Limited logo

HUTCHMED (China) Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

HUTCHMED (China) Limited Overview

HUTCHMED is a Hong Kong-headquartered, CK Hutchison-controlled biopharmaceutical company. Its business is discovering small-molecule targeted therapies in its Shanghai laboratories and taking them to market, increasingly worldwide. It has five China-approved in-house innovations:

  • fruquintinib (ELUNATE in China; FRUZAQLA elsewhere via Takeda, approved or launched in 41 countries)

  • surufatinib (SULANDA)

  • savolitinib (ORPATHYS, partnered with AstraZeneca)

  • fanregratinib (ATLED, conditionally approved August 2026)

  • sovleplenib, whose ITP and wAIHA NDAs are under priority review in China

The 2025 divestment of its Shanghai Hutchison Pharmaceuticals stake left it with roughly US$1.37bn of cash and little debt. That cash is funding a pivot toward its proprietary Antibody-Targeted Therapy Conjugate (ATTC) platform, which pairs targeted-inhibitor payloads with antibodies; the September 2026 GSK licence for HMPL-A830 validated the platform externally. HUTCHMED has been profitable for three consecutive years (2023–2025). Investors now judge it as a capital-efficient China-origin innovator whose value depends on global partnering rather than on China sales alone.

Company's own description

HUTCHMED describes itself as an innovative, commercial-stage biopharmaceutical company. It says it is committed to the discovery, global development and commercialisation of targeted therapies and immunotherapies for cancer and immunological diseases. It emphasises that, from inception, it has taken in-house-discovered candidates to patients worldwide. Its first medicines are marketed in China, and the first of them, fruquintinib, is also approved in the US, Europe and Japan. (Source: "About HUTCHMED" boilerplate, 2026 press releases.)

Independent characterisation

HUTCHMED runs a hybrid model with four parts:

  1. Discovery engine (Shanghai). Roughly two decades of kinase-inhibitor chemistry have produced every marketed product in-house. Selectivity is the stated design principle.

  2. China commercial operation. An in-house oncology salesforce sells SULANDA and promotes ELUNATE, under a services arrangement with Eli Lilly, which historically held China commercial rights. It also supports ORPATHYS, which AstraZeneca commercialises.

  3. Out-licensing for ex-China value. Takeda holds FRUZAQLA rights outside China; AstraZeneca holds global savolitinib rights; GSK (2026) holds ex-Greater China rights to HMPL-A830. HUTCHMED receives upfronts, milestones, manufacturing revenue and royalties.

  4. Legacy "Other Ventures." This is mainly a low-margin prescription-drug distribution business in China. It also held, until 2025, a 50% share of the SHPL cardiovascular joint venture; HUTCHMED now retains 5%.

Revenue model mix

Revenue typeFY2025% of total
Marketed oncology products (manufacturing revenue, royalties, promotion services, direct sales)214.439.1%
Takeda upfront amortisation, regulatory milestones, R&D services51.69.4%
Other licensing / R&D services (incl. AstraZeneca milestone)19.53.6%
Other Ventures (prescription drug distribution)263.047.9%
Total548.5100%

Source: FY2025 results announcement, 5 Mar 2026.

The mix therefore has three layers:

  • Products (~39%), which includes royalty and manufacturing income from partners.

  • Licensing/milestones (~13%), which is lumpy.

  • Distribution (~48%), which carries low margin.

There is no subscription revenue. Partner-reported "in-market sales" of US$524.7M in FY2025 were far larger than the US$214.4M of consolidated product revenue. The gap exists because, for FRUZAQLA and ORPATHYS, HUTCHMED books only royalties and manufacturing revenue.

Value-chain position, customers and end-markets

HUTCHMED spans discovery through to commercial manufacturing; it holds in-house API and formulation capability for its products. Ex-China, it relies on partners for commercialisation.

Direct customers: Chinese pharmaceutical distributors and hospitals for SULANDA and the distribution business; partners Takeda, AstraZeneca, Lilly and now GSK.

End users: oncology and haematology patients.

End-markets: colorectal, lung (EGFRm/MET-driven NSCLC), neuroendocrine, endometrial, renal, gastric, biliary (intrahepatic cholangiocarcinoma) cancers; lymphoma; and immune cytopenias (ITP, wAIHA).

Strategy

Stated strategy (paraphrased themes from the FY2025 Annual Report and 2026 results)

  1. Global oncology portfolio anchored in differentiated innovation. The Chairman (H1 2026) framed the future around first-in-class ATTC payload platforms and other emerging large-molecule modalities, aiming for front-line use in combination with standard of care.

  2. Partner-led global commercialisation. HUTCHMED applies the FRUZAQLA–Takeda template, using multinationals to accelerate ex-China development and marketing. The GSK HMPL-A830 deal (September 2026) is its first ATTC application. Management signals that further ATTC partnerships "are under discussion."

  3. Financial self-sufficiency. The company aims to fund discovery and early clinical work from commercial earnings. Profits were delivered in 2023, 2024 and 2025, and H1 2026 was profitable.

  4. Sustainable China commercial model. Following the 2025 compliance tightening, management restructured the sales organisation to fit China's regulatory direction. It is now focusing on key hospitals, guideline upgrades and NRDL expansion.

  5. AI-enhanced discovery. Expanded talent and AI capabilities in discovery were cited in both the FY2025 and H1 2026 statements.

  6. Capital deployment. Cash of ≈US$1.37bn is earmarked to accelerate ATTC development and to explore in-licensing, M&A and investment opportunities.

Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetail
SHPL divestmentJan 2025 (closed Apr 2025)US$608.5M cash; refocus on core business
ATTC platform into the clinicOct 2025 – Sep 2026A251 (Dec 2025), A580 (Mar 2026), A830 (Sep 2026)
China commercial restructuring2,025Salesforce streamlining and enhanced compliance controls; S&A for oncology products fell to 15.8% of oncology product revenue
Partnering of sovleplenib ex-China2025–2026Partnership being sought
GSK licence (HMPL-A830)Sep 2026US$110M upfront; up to US$1.295bn total plus royalties
Sustainability target-setting cycle2,026New roadmap across five pillars (Innovation, Climate Action, Human Capital, Access to Healthcare, Ethics and Transparency)

Guidance

  • FY2026 Oncology/Immunology consolidated revenue guidance is US$330M–US$450M. It was issued in March 2026 and reiterated in July 2026. The comparable FY2025 figure was US$285.5M, so the range implies +16% to +58%. The top end likely assumes partnering income such as the GSK upfront.

  • No medium-term margin or EPS targets are published.

  • Historical guidance accuracy: FY2024 guidance was US$300M–400M against US$363.4M delivered (within range).

Products & Services

Oncology/Immunology: marketed products

Fruquintinib (ELUNATE in China; FRUZAQLA ex-China)

Mechanism: oral, highly selective inhibitor of VEGFR-1, -2 and -3.

China (ELUNATE): - Approved September 2018 for 3L mCRC.

  • Endometrial cancer indication (2L pMMR EMC with sintilimab) added in 2024; NRDL coverage extended in 2026.

  • 2L renal cell carcinoma with sintilimab approved May 2026, on FRUSICA-2: mPFS 22.2 vs 6.9 months against axitinib/everolimus; ORR 60.5% vs 24.3%.

  • Commercial arrangement: Lilly-related promotion services structure. HUTCHMED's revenue comprises manufacturing revenue, promotion and marketing service fees, and royalties.

Ex-China (FRUZAQLA, Takeda): - US approval November 2023, EU June 2024, Japan September 2024 (previously treated mCRC).

  • Approved or launched in 41 countries by July 2026.

Pricing model: HUTCHMED earns manufacturing revenue and tiered royalties from Takeda. Royalty rates are not publicly disclosed in the sources consulted.

In-market sales (FY2025): FRUZAQLA US$366.2M (+26%); ELUNATE US$100.1M (-13%).

In-market sales (H1 2026): FRUZAQLA US$185.4M (+14%; ex-US ≈+70% to US$68.9M); ELUNATE US$60.8M (+41%).

Surufatinib (SULANDA, China)

Mechanism: oral inhibitor of VEGFR, FGFR1 and CSF-1R; anti-angiogenic plus immuno-modulatory.

Indications: non-pancreatic NETs (2020) and pancreatic NETs (2021) in China.

Commercialisation: sold directly by HUTCHMED. The US NDA was not approved in 2022 (FDA required a multi-regional trial); that history is drawn from public record.

Recent performance: FY2025 sales fell 45% to US$27.0M on competition from new NRDL entrants. The H1 2026 rebound (+45% to US$18.4M) followed an upgrade to CSCO Level I recommendation over competing SSA products.

NRDL: renewed without a price cut (FY2025 call).

Lifecycle: a Phase II/III trial in 1L metastatic pancreatic ductal adenocarcinoma (combination with camrelizumab, nab-paclitaxel and gemcitabine) reported mPFS 7.2 vs 5.5 months (HR 0.499). The Phase III part was initiated in December 2025.

Savolitinib (ORPATHYS; partnered globally with AstraZeneca)

Mechanism: oral, highly selective MET TKI.

China approvals: - METex14 NSCLC: conditional approval 2021; full 1L/2L approval January 2025.

  • With TAGRISSO for 2L EGFRm MET-amplified NSCLC: June 2025 (SACHI).

  • 3L MET-amplified gastric cancer: conditional approval, announced 2 July 2026 (ORR 32.3%).

Ex-China: - Swissmedic temporary authorisation, February 2026, with TAGRISSO (SAVANNAH data).

  • US NDA submitted by AstraZeneca on 28 September 2026, based on SAFFRON (338 patients, 29 countries; statistically significant PFS and OS gains vs platinum doublet).

Economics: AstraZeneca commercialises; HUTCHMED receives manufacturing revenue, royalties and milestones.

Sales: in-market FY2025 US$28.9M (-36%); H1 2026 US$15.7M.

Fanregratinib (ATLED, China)

Mechanism: selective FGFR1/2/3 inhibitor.

Approval: conditional NMPA approval announced 27 August 2026 for previously treated FGFR2 fusion/rearrangement intrahepatic cholangiocarcinoma. Pivotal Phase II data: ORR 42.5%, mPFS 6.9 months, mOS 16.6 months.

Commercial status: launch economics not yet disclosed.

Tazemetostat (TAZVERIK; in-licensed from Epizyme/Ipsen for Greater China) — withdrawn

Mechanism: first-in-class EZH2 inhibitor.

History: conditionally approved in China in March 2025 for 3L EZH2-mutant follicular lymphoma; FY2025 revenue US$2.5M.

Withdrawal: in March 2026 Ipsen, the Marketing Authorisation Holder, voluntarily withdrew TAZVERIK from all its markets after emerging safety data from SYMPHONY-1. H1 2026 revenue was negative (-US$0.5M), reflecting returns.

Oncology/Immunology: late-stage and registrational pipeline

AssetMechanismLead programme(s)Status (Oct 2026)
Sovleplenib (HMPL-523)Selective oral Syk inhibitor2L ITP (ESLIM-01); 2L wAIHA (ESLIM-02, DRR 66.0%)ITP NDA resubmission accepted Feb 2026 (after NMPA required a lower impurity limit); wAIHA NDA accepted Apr 2026; both have priority review. Ex-China partner being sought
Savolitinib + osimertinibMET + EGFRSAFFRON (global, 2L+); SANOVO (China, 1L MET-overexpressed)SAFFRON: US NDA filed Sep 2026. SANOVO: positive PFS (31 Aug 2026), China filing expected. Both oral presentations at ESMO, 23–27 Oct 2026
HMPL-760Third-generation non-covalent BTK inhibitor (wild-type and C481S)2L R/R DLBCL with R-GemOxChina Phase III initiated Mar 2026
Surufatinib combinationVEGFR/FGFR1/CSF-1R1L metastatic PDACPhase III part initiated Dec 2025
HMPL-306 (ranosidenib)IDH1/2 inhibitorR/R AMLStatus not updated in 2026 materials reviewed

ATTC platform (Antibody-Targeted Therapy Conjugates)

CandidatePayload / antibodyStagePartner
HMPL-A251PI3K/PIKK inhibitor / anti-HER2 IgG1Global Phase I/IIa, first patient Dec 2025Wholly owned
HMPL-A580PI3K/PIKK inhibitor / anti-EGFR IgG1Global Phase I, first patient Mar 2026 (NSCLC, CRC, HNSCC, ESCC)Wholly owned
HMPL-A830KRAS inhibitor / anti-EGFR (second payload platform)Global Phase I initiated late Sep 2026 (NCT07718581)GSK ex-Greater China (Sep 2026)
Further candidatesUndisclosedPreclinicalGSK holds right of first negotiation on one earlier-stage ATTC

ATTCs conjugate HUTCHMED's proprietary small-molecule inhibitor payloads to antibodies, rather than the cytotoxins used in conventional ADCs. The design intent is a dual mechanism of action and lower off-tumour toxicity, so that the conjugates can be combined with chemotherapy or IO in earlier treatment lines.

Out-licensed immunology asset

IMG-007: is a non-T-cell-depleting, ADCC-silenced OX40 antagonist, discovered by HUTCHMED and developed by ImageneBio (formerly Inmagene). HUTCHMED holds ≈3.8% of ImageneBio.

  • Phase IIb in atopic dermatitis is ongoing, with topline expected Q4 2027. A Phase II in alopecia areata is planned for 2026.

Other Ventures

  • The business is prescription-drug marketing and distribution in China, with low margins. In 2026, management deliberately scaled down low-margin logistics sales to protect working capital.

  • HUTCHMED retains a 5% residual interest in SHPL (cardiovascular brands). A three-year transition arrangement was reported at the time of the deal.

Financial Narrative

Income statement

Sources and notes:

  • FY2021–FY2023 revenue and net income: FY2023 20-F, Item 5.

  • FY2022–FY2023 R&D and the FY2022 segment split: FY2023 results and Trinity Delta (29 Feb 2024).

  • FY2024–FY2025: FY2025 results.

  • FY2021 Oncology/Immunology (120.0) and R&D (299.1) come from the FY2021 report, as recalled. Other Ventures FY2021 is derived as total minus Oncology/Immunology. Verify all three against the FY2021 Annual Report.

  • Per-ADS EPS for FY2021–FY2023 is from a data aggregator (roic.ai); per-share values for those years are that figure divided by 5.

  • Operating income is calculated as revenue minus total operating expenses.

  • FY2025 pre-tax income includes the US$476.9M gain on the SHPL divestment.

  • HUTCHMED has never paid a dividend.

Margins (%)

Revenue CAGR, FY2021–FY2025: ≈11.4% a year (356.1 to 548.5). The path was not linear. It peaked in FY2023 on Takeda upfront recognition and then normalised.

H1 2026 snapshot (USD M):

  • Revenue 278.3

  • Cost of revenue 152.2; cost as a share of oncology product revenue improved to 33% from 39%

  • R&D 78.8

  • S&A 46.5

  • Operating result ≈ +0.9

  • Net income attributable 15.9

  • Basic EPS US$0.02 per share / US$0.09 per ADS

Balance sheet

Sources and notes:

  • FY2022–FY2023 cash comes from the FY2023 results. FY2024–FY2025 balance-sheet items come from the FY2025 results.

  • At 30 June 2026: cash and short-term investments US$1,374.8M, bank borrowings US$94.5M, equity US$1,260.8M, total assets US$1,736.4M.

  • The short-term/long-term debt split, goodwill and intangibles, and working capital were not disclosed in the summary statements consulted. Goodwill and intangibles are understood to be immaterial, since the pipeline is home-grown.

Cash flow

Sources and notes:

  • FY2025 results; FY2025 operating cash flow per the SEC XBRL summary (edgar.tools).

  • Operating cash flow was negative in FY2025 because the US$59.5M capital-gains tax on the SHPL sale is classed as operating, and because previously received Takeda upfront cash was being amortised. The SHPL proceeds (US$608.5M gross) sit in investing.

  • H1 2026: adjusted net cash inflow excluding financing was US$10.5M; capex US$5.6M; net cash used in financing US$2.9M.

  • Equity-award purchases are shares bought by a trustee for incentive plans. They are not a capital-return buyback.

Ratios

Further notes:

  • ROIC, the current ratio, interest coverage and the cash conversion cycle cannot be computed from the condensed disclosures consulted.

  • The company is in a large net-cash position, so leverage ratios are not meaningful constraints.

  • Interest income is a material contributor to "Other income" (US$61.0M in FY2025).

Commentary: trends, inflections and drivers

FY2021–FY2022: peak-investment years. R&D peaked at US$386.9M in FY2022 as HUTCHMED ran concurrent global Phase III programmes. These included FRESCO-2 for fruquintinib, SAFFRON, and US registration work for surufatinib. The FY2022 net loss reached US$360.8M. The November 2022 reprioritisation cut lower-probability programmes and set a self-funding objective.

FY2023: the Takeda inflection. The Takeda deal (US$400M upfront) was recognised mostly in 2023: US$280M in revenue, plus US$32M linked to US approval. Revenue nearly doubled to US$838M and produced the company's first profit (US$100.8M). R&D fell 22% as late-stage trials completed.

FY2024: normalisation. With no large upfront to recognise, revenue fell to US$630.2M. Profitability held (US$37.7M) on FRUZAQLA royalties, a US$20M Takeda commercial milestone and interest income.

FY2025: a China commercial reset plus the SHPL gain. Consolidated oncology product revenue fell 21%. Three drivers stand out:

  • Stricter commercial compliance controls and a salesforce streamlining hurt ELUNATE in H1 2025.

  • New NRDL competitors eroded SULANDA.

  • Competition in the METex14 segment hit ORPATHYS.

H2 2025 showed a clear inflection: China product revenue rose 23% over H1. R&D fell further, to US$148.3M. Headline net income of US$456.9M is dominated by the US$415.8M after-tax SHPL gain. Excluding it, attributable profit was about US$41M.

H1 2026: recovery, with operating profitability near breakeven before other income. ELUNATE grew 41% and SULANDA 45%, and FRUZAQLA's ex-US sales grew ≈70%. R&D re-accelerated (+9%) as ATTC trials began. Lower SHPL equity income reduced "Other items" to US$15.1M from US$42.2M. Net income attributable was US$15.9M.

Forward drivers:

  • the GSK upfront (US$110M, payable at closing);

  • possible SAFFRON-linked AstraZeneca milestones;

  • NRDL inclusion for the RCC indication;

  • sovleplenib launches;

  • the cost of scaling ATTC global trials.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

SegmentFY2023FY2024FY2025

Oncology/Immunology revenue (USD Mn)

528.6363.4285.5

Other Ventures revenue (USD Mn)

309.4266.8263.0

Total revenue (USD Mn)

838.0630.2548.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2023FY2024FY2025

Oncology/Immunology YoY growth (%)

223-31-21

Other Ventures YoY growth (%)

18-14-1

Oncology/Immunology share of revenue (%)

63.157.752.1

Other Ventures share of revenue (%)

36.942.347.9

Revenue by Segment (FY2021–FY2025)

SegmentFY2021FY2022FY2023FY2024FY2025

Oncology/Immunology (USD Mn)

-291.7-385.451.2-10.0—

Other Ventures (USD Mn)

142.954.650.347.725.5

Business Lines

LineFY2024FY2025

FRUZAQLA consolidated revenue (USD Mn)

110.889.4

ELUNATE consolidated revenue (USD Mn)

86.376.9

SULANDA consolidated revenue (USD Mn)

49.027.0

ORPATHYS consolidated revenue (USD Mn)

24.518.6

TAZVERIK consolidated revenue (USD Mn)

0.92.5

Takeda upfront, milestones and R&D services (USD Mn)

67.051.6

Other revenue, R&D services and licensing (USD Mn)

24.919.5

Business Lines (Half-Yearly)

LineH1 2025H1 2026Change

Oncology products

99.1121.4+23%

Takeda-related

29.520.7-30%

Other licensing/R&D

14.920.2

+35% (incl. US$18.1M Lilly milestone)

Oncology/Immunology total

143.5162.3+13%

Other Ventures

134.2116.0-14%

Group total

277.7278.3

flat (-4% CER)

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (USD Mn)

356.1426.4838.0630.2548.5

Oncology/Immunology revenue (USD Mn)

120.0163.8528.6363.4285.5

Other Ventures revenue (USD Mn)

236.1262.6309.4266.8263.0

Cost of revenue (USD Mn)

———348.9336.3

Gross profit (USD Mn)

———281.3212.2

R&D expense (USD Mn)

299.1386.9302.0212.1148.3

Selling and administrative expense (USD Mn)

———112.9103.0

Operating income (USD Mn)

———-43.7-39.2

Pre-tax income before equity earnings (USD Mn)

———-1.1498.7

Net income attributable to HUTCHMED (USD Mn)

-194.6-360.8100.837.7456.9

Basic EPS per ordinary share (USD)

-0.25-0.430.120.040.53

Diluted EPS per ordinary share (USD)

———0.040.52

Basic EPS per ADS (USD)

-1.23-2.130.590.222.66

Dividends per share (USD)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

———44.638.7

Operating margin (%)

———-6.9-7.1

Net margin (%)

-54.6-84.612.06.083.3

R&D as % of revenue (%)

84.090.736.033.727.0

Balance Sheet

MetricFY2022FY2023FY2024FY2025

Cash, cash equivalents and short-term investments (USD Mn)

631.0886.3836.11,367.3

Accounts receivable (USD Mn)

——155.5126.8

Total assets (USD Mn)

——1,274.21,753.1

Bank borrowings, total debt (USD Mn)

——82.893.2

Net cash, cash less borrowings (USD Mn)

——753.31,274.1

Deferred revenue (USD Mn)

——98.551.5

Total liabilities (USD Mn)

——502.3501.8

Shareholders' equity (USD Mn)

——759.91,237.9

Investment in equity investees (USD Mn)

——77.810.9

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (USD Mn)

————-64.7

Capital expenditure (USD Mn)

———17.914.1

Adjusted Group net cash flow excl. financing, non-GAAP (USD Mn)

———-19.5523.3

Purchases for equity awards (USD Mn)

———36.1—

Dividends paid (USD Mn)

00000

Share buybacks (USD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2024FY2025

ROE, on average equity (%)

—45.7

ROE excluding SHPL gain (%)

—4.1

ROA, on average assets (%)

—30.2

Debt/Equity (x)

0.110.08

Asset turnover (x)

—0.36

Revenue by Region and Revenue by Region (%)

Region (proxy)FY2024FY2025

Ex-China, Takeda-related (USD Mn)

177.8141.0

China and other (USD Mn)

452.4407.5

Ex-China share of total (%)

28.225.7

Products

Product (market)FY2024FY2025

FRUZAQLA, ex-China (USD Mn)

290.6366.2

ELUNATE, China (USD Mn)

115.0100.1

SULANDA, China (USD Mn)

49.027.0

ORPATHYS, China (USD Mn)

45.528.9

TAZVERIK, China (USD Mn)

0.92.5

Total oncology in-market (USD Mn)

501.0524.7

Products (Half-Yearly)

Product (market)H1 2025H1 2026

FRUZAQLA, global ex-China (USD Mn)

162.8185.4

ELUNATE (USD Mn)

43.060.8

SULANDA (USD Mn)

12.718.4

ORPATHYS (USD Mn)

15.215.7

China in-market total (USD Mn)

71.694.4

Value by Reference Point

Reference pointValue

AIM price (8 Oct 2026)

≈209p

AIM 52-week range (as of Jul 2026)

150.48p – 292.00p

AIM price around the H1 2025 SHPL announcement (2 Jan 2025)

≈246p

Nasdaq ADS (late Sep 2026, implied from ≈US$2.46bn market cap / 174.45M ADS)

≈US$14.1

Share Price

MetricOct 2021Oct 2022Oct 2023Oct 2024Oct 2025

ADS price (USD)

29.428.8419.4818.0014.68

Valuation Snapshot

MultipleValueBasis

Market cap

≈US$2.46bn

Nasdaq-based

Enterprise value

≈US$1.18bn

Market cap − cash and short-term investments (US$1.375bn) + borrowings (US$0.095bn), 30 Jun 2026

P/E (LTM, net income ≈US$17.8M)

≈138x

LTM = FY2025 − H1 2025 + H1 2026; excludes the 2025 SHPL gain

P/E (FY2025 reported)

≈5.4x

Distorted by the US$415.8M gain

EV/Sales (LTM revenue ≈US$549M)

≈2.1x

—

EV/Oncology-Immunology revenue (LTM ≈US$304M)

≈3.9x

—

P/B (equity US$1.26bn)

≈1.95x

—

Analyst Conclusions

Management guidance

  • FY2026 Oncology/Immunology consolidated revenue of US$330–450M, reiterated on 30 July 2026.

  • Management intends to accelerate global ATTC development and to explore investments.

  • The company aims to stay financially self-sufficient.

Consensus expectations

  • Third-party aggregators cited ≈16% annual revenue growth over three years (Simply Wall St, 2025).

Bull case

  1. The ATTC platform has external validation and optionality. GSK paid US$110M upfront for a Phase I-ready asset, with up to US$1.185bn more in milestones. GSK also holds a right of first negotiation on another ATTC. Two further wholly-owned ATTCs (A251, A580) are already dosing patients, and each could support a comparable deal.

  2. A second global product is in sight. SAFFRON produced statistically significant OS as well as PFS against chemotherapy, and the US NDA is filed. Approval in 2027–2028 would add milestone and royalty streams alongside FRUZAQLA, whose ex-US sales grew ≈70% in H1 2026.

  3. The valuation is underpinned by cash. Enterprise value is only ≈US$1.2bn, about half the market capitalisation. That EV covers:

    • five China-approved drugs;

    • a recovering China business (+32% in-market in H1 2026);

    • two sovleplenib NDAs under priority review;

    • FRUZAQLA royalties.

Bear case

  1. Earnings are thin underneath the headlines. Strip out the 2025 SHPL gain and the company earned about US$41M in FY2025 and US$15.9M in H1 2026. Equity income from SHPL has largely gone, and Takeda service revenue is shrinking (−30% in H1 2026).

  2. China execution risk persists. The 2025 compliance shock showed how quickly sales can fall (SULANDA −45% in FY2025). Most new launches are conditional approvals in niche indications (ICC, MET-amplified gastric cancer), and every new indication faces NRDL price negotiation.

  3. Governance and geopolitics weigh on the stock. The CEO has been on medical leave for more than a year, and the Acting CEO also serves as CFO. CK Hutchison controls 38.1%. US–China policy risk (tariffs, BIOSECURE-type rules) has kept the shares roughly 50% below their October 2021 level, despite three profitable years.

Key catalysts and monitorables (next 12 months)

ESMO 2026 (23–27 Oct, Madrid): full SAFFRON (Presidential Symposium) and SANOVO data, including hazard ratios and OS maturity.

GSK deal: closing and receipt of the US$110M upfront, and whether it is recognised within FY2026 guidance.

FDA: acceptance of the ORPATHYS + TAGRISSO NDA, the review designation, and any AstraZeneca milestone.

NMPA: decisions on sovleplenib in ITP and wAIHA; a SANOVO filing in China.

NRDL 2026 negotiations: ELUNATE RCC, ATLED and ORPATHYS gastric cancer.

ATTC first-in-human data: first disclosures for A251 and A580, likely in 2027; any second ATTC partnership.

CEO: Dr Su's return, or a permanent CEO appointment.

FY2026 results (~March 2027): whether Oncology/Immunology revenue lands within US$330–450M.

Analyst verdict

HUTCHMED in late 2026 is a strategically cleaner company than at any point in its history. Its non-core joint ventures are almost fully monetised. Its balance sheet carries roughly US$1.28bn of net cash. Its pipeline has finally produced the two outcomes the market had waited years for: a global Phase III showing an overall-survival benefit for savolitinib, and a Big Pharma licence that validates the ATTC platform before human efficacy data exist. Together these change the investment case. HUTCHMED can no longer fairly be described as merely a China-centric kinase-inhibitor house living off one global royalty stream.

Several things temper the enthusiasm. Reported profits look strong but rest on a thin operating base: excluding the 2025 divestment gain, net income runs at roughly break-even to modestly positive levels. Partner service revenues are rolling off. China remains structurally hostile to pricing, and the 2025 compliance episode showed that sales can halve within a year. Leadership is also an issue: running a pivot of this ambition with an acting CEO who is also the CFO is not ideal, and the board will eventually need to resolve it.

The equity case therefore rests on asymmetric optionality priced at a low enterprise value. An EV of about US$1.2bn has to cover:

  • FRUZAQLA royalties growing in double digits;

  • a plausible 2027–2028 US approval for ORPATHYS + TAGRISSO;

  • two China launches of sovleplenib;

  • three clinical-stage ATTCs, one of which already carries up to US$1.295bn in potential deal value.

The next twelve months are rich in catalysts and largely binary: ESMO data quality, FDA acceptance, NMPA decisions and first ATTC safety signals. The case would be invalidated if FY2026 Oncology/Immunology revenue fell below the US$330M floor, or if ATTC dose escalation disclosed dose-limiting toxicity that undermined the platform thesis.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / background

Dr Weiguo Su

CEO (on leave of absence since 25 Aug 2025) and Chief Scientific Officer; Executive Director

Joined in 2005 and led the discovery engine for ~20 years; CEO since 2022. Previously a medicinal chemist at Pfizer; PhD (chemistry), Harvard, with postdoctoral work under E.J. Corey. Biographical details are from public record; verify against the 20-F

Johnny Cheng Chig Fung

Acting CEO (since 25 Aug 2025), CFO, Executive Director

CFO since 2008. Earlier career at Bristol-Myers Squibb (China) and KPMG/PwC-era audit roles (verify)

Lorenso Chiu

Deputy CFO

Presented H1 2026 financials

George Yuan

Head of Commercial (China)

Presented on the H1 2026 call

Dr Dai (full name per 20-F)

Head of Discovery and Global Portfolio Management

Presented on the H1 2026 call

David Ng

Head of Investor Relations and Capital Strategies

—

Edith Shih

Company Secretary (also Non-executive Director)

Long-serving CK Hutchison executive

Board of Directors

DirectorRoleCommittees

Dr Dan Eldar

Non-executive Chairman

Technical Committee (member)

Dr Weiguo Su

Executive Director (CEO*, CSO)

Technical

Johnny Cheng

Executive Director (Acting CEO, CFO)

Sustainability

Edith Shih

Non-executive Director, Company Secretary

Sustainability (Chair), Remuneration

Ling Yang

Non-executive Director (MD, The Carlyle Group; co-head Carlyle Asia Healthcare)

—

Dr Renu Bhatia

INED; Senior and Lead INED (from May 2026)

Nomination (Chair), Remuneration (Chair), Audit, Technical

Dr Chaohong Hu

INED

Technical (Chair), Audit, Nomination

Prof. Tan Shao Weng, Daniel

INED

Sustainability, Technical

Wong Tak Wai

INED

Audit (Chair), Remuneration

Major Shareholders

HolderStakeSource

CK Hutchison Holdings (via Hutchison Healthcare Holdings Ltd)

38.1% (332.5M shares)

FY2025 20-F (13 Feb 2026)

AEGON-Industrial Fund Management

≈19.9M shares (≈2.3%)

Fidelity UK factsheet (aggregated filings)

AIFMC HeYi Allocation (LOF)

≈14.5M (≈1.7%)

Same

Vanguard Group

≈14.3M (≈1.6%)

Same

GF Fund Management

≈10.6M (≈1.2%)

Same

GF CSI Hong Kong Brand New Drug ETF (QDII)

≈10.6M (≈1.2%)

Same

Competitive Landscape

Competitor Detail

FranchiseKey competitors (product)HUTCHMED positioning

3L+ mCRC (fruquintinib)

Bayer (Stivarga/regorafenib); Taiho/Servier (Lonsurf ± bevacizumab); Chinese anti-angiogenics

FRUZAQLA is differentiated by its oral, chemo-free regimen, tolerability and low pill burden. ELUNATE holds the leading 3L mCRC share in China (company claim)

NETs (surufatinib)

Pfizer (Sutent/sunitinib); Novartis (Afinitor/everolimus); somatostatin analogues (Novartis, Ipsen); new NRDL entrants in China

CSCO Level I recommendation (2026); leads the NET TKI segment in China

MET-driven NSCLC (savolitinib)

Novartis (Tabrecta/capmatinib); Merck KGaA (Tepmetko/tepotinib); J&J (Rybrevant/amivantamab ± lazertinib); China MET TKIs (e.g. Haihe/Avistone glumetinib, Haihe vebreltinib)

Biomarker-defined combination with market-leading TAGRISSO. SAFFRON is the first global Phase III to show OS benefit in post-osimertinib MET-driven disease

FGFR2 ICC (fanregratinib)

Incyte (Pemazyre/pemigatinib); Taiho (Lytgobi/futibatinib)

Late entrant in China; pricing and NRDL will be decisive

ITP/wAIHA (sovleplenib)

Rigel (Tavalisse/fostamatinib); Sanofi (rilzabrutinib); TPO-RAs (Novartis Promacta, others); Chinese biosimilars and generics

Potential first selective Syk inhibitor approved in China

ADC/conjugates (ATTC)

Daiichi Sankyo/AstraZeneca (Enhertu, Datroway); Kelun-Biotech/Merck; Hengrui; BioNTech/Duality; RemeGen; pan-RAS developers (Revolution Medicines)

Novel non-cytotoxic payload class; validated by GSK. Clinical proof is still pending

China oncology broadly

Jiangsu Hengrui, BeOne (BeiGene), Innovent, Hansoh, Zai Lab, Akeso, CSPC

Smaller, more focused, with a cash-rich balance sheet

Peer Comparison FY2024

CompanyFY2024 revenueRevenue growthProfitabilityR&D intensity

HUTCHMED

US$630.2M

−25%

Net income US$37.7M

34% of revenue

BeOne Medicines (BeiGene)

≈US$3.8bn

≈+55%

Net loss

High (>50%)

Jiangsu Hengrui

≈RMB28.0bn

≈+23%

Profitable

≈ low-20s %

Zai Lab

≈US$0.40bn

≈+50%

Net loss

High

Recent Developments

--

Company Snapshot

$548.5M

Revenue

1,800

Employees

2000

Founded

Queen's Road Central, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Balance-sheet strength: US$1,374.8M of cash and short-term investments against US$94.5M of bank borrowings (30 Jun 2026 interim).
  • Global regulatory track record: FRUZAQLA is approved in the US (Nov 2023), EU (Jun 2024) and Japan (Sep 2024), and approved or launched in 41 countries (H1 2026).
  • Recurring profitability: net income in FY2023 (US$100.8M), FY2024 (US$37.7M), FY2025 (US$456.9M) and H1 2026 (US$15.9M).
  • Validated discovery engine: five in-house molecules approved in China. ATLED, approved in August 2026, is the latest.
  • Partner quality: AstraZeneca, Takeda, Lilly and now GSK. The GSK deal is worth up to US$1.295bn.
  • Late-stage data quality: SAFFRON is positive for both PFS and OS (Aug 2026); FRUSICA-2 mPFS was 22.2 vs 6.9 months; ESLIM-02 DRR was 66.0%.
  • Cost discipline: oncology product S&A was cut to 15.8% of oncology product revenue in FY2025 from 16.6%. Oncology cost of revenue fell to 33% of oncology product revenue in H1 2026.

Weaknesses

  • Declining consolidated revenue: −13% in FY2025 to US$548.5M. Oncology product revenue fell 21%.
  • Earnings quality: 91% of FY2025 net income came from a one-off divestment gain (US$415.8M of US$456.9M).
  • Royalty-only ex-China capture: FY2025 FRUZAQLA consolidated revenue was US$89.4M against US$366.2M of in-market sales (≈24%).
  • Product setbacks: SULANDA in-market sales fell 45% in FY2025 on new NRDL competition. TAZVERIK was withdrawn in March 2026. Sovleplenib's ITP NDA had to be resubmitted to meet impurity limits.
  • Leadership interim: the CEO has been on leave since August 2025, and the Acting CEO also serves as CFO.
  • Low-margin revenue mix: Other Ventures distribution makes up 48% of FY2025 revenue but contributed only US$3.8M of attributable profit in H1 2026.

Opportunities

  • US approval of ORPATHYS + TAGRISSO: NDA filed 28 Sep 2026. This would be HUTCHMED's second global product, with milestone and royalty potential.
  • ATTC partnering: GSK holds a right of first negotiation on one more ATTC, and management says other multinational discussions are under way.
  • Sovleplenib launches in China: two indications under priority review, with ITP and wAIHA patient pools cited by IQVIA.
  • SANOVO 1L filing in China: this would move savolitinib into front-line treatment.
  • FRUZAQLA reimbursement expansion: ex-US growth of ≈70% in H1 2026, and reimbursement in only about 20 countries so far.
  • NRDL listing for ELUNATE's RCC indication, plus SULANDA's PDAC Phase III, broaden the China base.
  • Deploying ≈US$1.3bn of net cash in in-licensing or M&A (stated intent, FY2025 results).

Threats

  • China pricing and compliance regime: 2025 compliance tightening cut H1 2025 China sales by 29–50% by product.
  • Competition: new NRDL entrants (SULANDA), METex14 competitors (ORPATHYS), and fast-moving ADC and pan-RAS fields (ATTC).
  • US policy: the Medicare Part D redesign dampened US FRUZAQLA in 2025, and potential pharmaceutical tariffs or BIOSECURE-type measures add risk.
  • Geopolitical and listing risk: US–China tensions. HUTCHMED's 2022 identification under the HFCAA (later resolved) shows the exposure.
  • Partner concentration: Takeda revenue is declining as R&D services wind down (−30% in H1 2026).
  • Clinical risk in first-in-human ATTC trials: dose escalation of A251 and A580 is ongoing, and no clinical efficacy has yet been disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025SHPL 45% divestment completed; US$608.5M receivedCash reached about US$1.4bn; recurring equity income lost
Jun 2025NMPA approves ORPATHYS + TAGRISSO (SACHI) for 2L EGFRm MET-amplified NSCLCThird lung indication; US$11.0M AstraZeneca milestone
Jun 2025Fruquintinib + sintilimab sNDA (2L RCC) accepted by NMPALed to May 2026 approval
Mid-2025SACHI data at ASCO; SAVANNAH at ELCCEvidence base for global filings
H1 2025China sales decline amid compliance tightening and salesforce restructuringELUNATE −29%, SULANDA −50%, ORPATHYS −41% in H1 2025 in-market
Aug 2025SANOVO enrolment completed1L EGFRm/MET-overexpressed readout set up
25 Aug 2025CEO Dr Weiguo Su on medical leave; CFO Johnny Cheng becomes Acting CEOKey-person and governance concentration risk
Oct 2025FRUSICA-2 Phase III at ESMO (mPFS 22.2 vs 6.9 months); HMPL-A251 preclinical data at AACR-NCI-EORTC; R&D day (31 Oct)ATTC platform introduced to investors
5 Nov 2025SAFFRON enrolment completed (338 patients)Global registration path
Nov 2025HMPL-A251 INDs cleared (China, US)First ATTC IND
Dec 2025First patient dosed, HMPL-A251; fanregratinib NDA accepted (priority); savolitinib GC sNDA accepted (priority, 30 Dec); surufatinib PDAC Phase III initiated; PDAC Phase II data at ESMO AsiaMultiple pipeline steps
6 Jan 2026ESLIM-02 Phase III (sovleplenib, wAIHA) meets primary endpointSecond sovleplenib indication
13 Jan 2026SACHI published in The LancetScientific validation
Feb 2026Swissmedic temporary authorisation of savolitinib + TAGRISSO; sovleplenib ITP NDA resubmission acceptedFirst Western savolitinib authorisation; ITP review restarted
5 Mar 2026FY2025 results: revenue US$548.5M (−13%); net income US$456.9M; FY2026 guidance US$330–450M; 20-F filedThird consecutive profitable year
6 Mar 2026Prof. Tony Mok to retire at the AGM; committee reshuffleBoard renewal
Mar 2026HMPL-A580 first patient; HMPL-760 Phase III (DLBCL) initiated (23 Mar); Ipsen withdraws TAZVERIK globallyATTC #2 in clinic; small product loss
9 Apr 20262025 Annual Report and Sustainability Report published—
29 Apr 2026Sovleplenib wAIHA NDA accepted with priority review—
12 May 2026AGM; board reconstituted (Dr Bhatia becomes Senior INED)—
21 May 2026NMPA approves ELUNATE + TYVYT for 2L RCCTriggered US$18.1M Lilly milestone; NRDL opportunity
Jun 2026ESLIM-02 at EHA (DRR 66.0%); GC data at ASCO and in Nature Medicine; fanregratinib pivotal data at ESMO GIData flow
2 Jul 2026NMPA approves ORPATHYS for 3L MET-amplified gastric cancerFourth ORPATHYS approval
Jul 2026HMPL-A830 CTA approved (China) and US IND cleared; MSCI ESG upgrade to AA—
30 Jul 2026H1 2026 results: China in-market +32%; net income US$15.9M; guidance reiteratedShares fell ≈5% on the day
17 Aug 2026SAFFRON Phase III positive for both PFS and OSSupports a global filing; potential second global product
27 Aug 2026ATLED (fanregratinib) conditionally approved in China (FGFR2 ICC)Fifth in-house China-approved innovative drug
31 Aug 2026SANOVO Phase III positive (PFS significant; OS clinically meaningful)Front-line expansion in China
3 Sep 2026GSK licence for HMPL-A830 (US$110M upfront; up to US$1.295bn)Shares +17% on the day
24 Sep 2026SAFFRON (Presidential Symposium) and SANOVO selected for ESMO 2026 orals—
27–28 Sep 2026HMPL-A830 Phase I (Ia) initiated in ChinaPhase I is HUTCHMED's responsibility under the GSK deal
28 Sep 2026AstraZeneca submits US NDA for ORPATHYS + TAGRISSOFDA decision plausibly in 2027

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement: Revenue & Gross Profit: Revenue rose from USD 356.1 Mn in FY2021 to USD 548.5 Mn in FY2025.
HUTCHMED (China) Limited — Income Statement: Revenue & Gross Profit
Series (USD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue356.1426.4838630.2548.5
Oncology/Immunology revenue120163.8528.6363.4285.5
Other Ventures revenue236.1262.6309.4266.8263
Cost of revenue———348.9336.3
Gross profit———281.3212.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. HUTCHMED, "HUTCHMED Reports 2025 Full Year Results and Business Updates," 5 Mar 2026 (GlobeNewswire, via StockTitan) (stocktitan.net)
  2. HUTCHMED, "HUTCHMED Reports 2026 Interim Results," 30 Jul 2026 (RNS via Investegate) (investegate.co.uk)
  3. HUTCHMED, licensing agreement with GSK for HMPL-A830, 3 Sep 2026 (stocktitan.net)
  4. HUTCHMED, submission of US NDA for ORPATHYS plus TAGRISSO, 28 Sep 2026 (stocktitan.net)
  5. HUTCHMED, Form 20-F FY2023 (SEC) (sec.gov)
  6. HUTCHMED, Form 20-F FY2025 (SEC), Item 7 (sec.gov)
  7. HUTCHMED, FY2023 results (SEC Exhibit 99.1) (sec.gov)
  8. Trinity Delta, FY23 results note (29 Feb 2024) (trinitydelta.org)
  9. Trinity Delta, SAFFRON note (18 Aug 2026) (trinitydelta.org)
  10. HUTCHMED, Acting CEO appointment, 25 Aug 2025 (GlobeNewswire) (globenewswire.com)
  11. HUTCHMED, intended retirement of INED, 6 Mar 2026 (BioSpace) (biospace.com)
  12. Board composition, 13 May 2026 (Tiger Brokers / Bulletin Express) (itiger.com)
  13. HUTCHMED, SHPL divestment RNS, 2 Jan 2025 (FCA NSM) (data.fca.org.uk)
  14. HUTCHMED, ESMO 2026 data announcement, 24 Sep 2026 (investegate.co.uk)
  15. OncLive, ATLED approval, 28 Aug 2026 (onclive.com)
  16. Total Voting Rights RNS, 31 Dec 2025 (LSE.co.uk) (lse.co.uk)
  17. AIM share price history (shareprices.com): and: lse.co.uk · shareprices.com
  18. ADS price history (digrin) (digrin.com)
  19. etnet HKEX company profile (auditor, address, shareholding) (etnet.com.hk)
  20. Fidelity UK factsheet (employees, top holders) (fidelity.co.uk)
  21. edgar.tools FY2025 XBRL summary (app.edgar.tools)
  22. Clinical Trial Vanguard, SAFFRON enrolment (Nov 2025) (clinicaltrialvanguard.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →